EV-302: Updated Analysis From the Phase 3 Global Study

At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, Guru Sonpavde, MD, of AdventHealth Cancer Institute, provides an update on the latest analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab vs chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma.

He speaks to whether subgroup analyses have led to further understandings of the efficacy and tolerability of this combination, especially in patients with challenging features like liver metastases or poor performance status.